Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GC 2107

Drug Profile

GC 2107

Alternative Names: CB02-0133; GC-2107; GC4401; GCC-2107; GCC-4401; GCC-4401C; I Fxa - LegoChem Biosciences; LCB-02-0133; Nokxaban

Latest Information Update: 01 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LegoChem Biosciences
  • Class Anticoagulants; Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Embolism; Stroke; Venous thromboembolism

Most Recent Events

  • 01 Jun 2018 Phase-II clinical trials in Embolism (Prevention) in USA (PO) (LegoChem Biosciences pipeline, June 2018)
  • 01 Jun 2018 Phase-II clinical trials in Stroke (Prevention) in USA (PO) (LegoChem Biosciences pipeline, June 2018)
  • 01 Jun 2018 Phase-II clinical trials in Venous thromboembolism (Prevention) in USA (PO) (LegoChem Biosciences pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top